| Literature DB >> 16446426 |
Jongdae Lee1, Christina C N Wu, Ki Jeong Lee, Tsung-Hsien Chuang, Kyoko Katakura, Yu-Tsueng Liu, Michael Chan, Rommel Tawatao, Michelle Chung, Carol Shen, Howard B Cottam, Michael M C Lai, Eyal Raz, Dennis A Carson.
Abstract
IFN-alpha is used to suppress the replication of hepatitis C virus (HCV) in chronically infected patients with partial success. Here we present evidence showing that a ligand of Toll-like receptor 7 (TLR7) can induce anti-HCV immunity not only by IFN induction, but also through an IFN-independent mechanism. Human hepatocyte line Huh-7 carrying an HCV replicon expressed TLR7, and activation of the receptor induced several antiviral genes including IFN regulatory factor-7. Inhibitors of the enzyme inosine monophosphate dehydrogenase augmented both IFN-dependent and -independent antiviral effect. Prolonged exposure of Huh-7 cells to a TLR7 ligand [SM360320 (9-benzyl-8-hydroxy-2-(2-methoxyethoxy)adenine)], alone or in combination with an inosine monophosphate dehydrogenase inhibitor, reduced HCV levels dose dependently. Immunohistochemical analysis of livers shows that TLR7 is expressed in hepatocytes of normal or HCV-infected people. Because TLR7 agonists can impede HCV infection both via type I IFN and independently of IFN, they may be considered as an alternative treatment of chronic HCV infection, especially in IFN-alpha-resistant patients.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16446426 PMCID: PMC1413670 DOI: 10.1073/pnas.0510801103
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205